The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL). More >
Welcome to Focus on MCL
The FocusOnMCL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by mantle cell lymphoma (MCL).
We invite you to browse the site to learn more about MCL.
Getting the Facts
Mantle cell lymphoma is a rare form of non-Hodgkin lymphoma (NHL), constituting only six percent of all NHL cases in the United States. It is considered an aggressive B-cell lymphoma and gets its name because mantle cell tumors are composed of cells that come from the “mantle zone” of the lymph node.
Recent research into mantle cell lymphoma has led to significant advancements in the understanding of the disease. Research continues on multiple fronts to develop better treatments for MCL patients. We hope you will find the information presented here useful in understanding your disease and discussing it with your healthcare team.